Kleanthis G. Xanthopoulos, President and CEO at Regulus Therapeutics Inc. (RGLS), sold 200,000 shares at $17.73 ($3.4M) on 2015-04-21, disclosed to the SEC on 2015-04-21.
Scheduled sale ($3.4M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.94 | 73,929 | $1.3M | 36.5% |
| 2 | $16.85 | 66,071 | $1.1M | 32.5% |
| 3 | $17.73 | 60,000 | $1.1M | 31.0% |
| Total | $17.15 avg | 200,000 | $3.4M | 100% |
| Filing → |
| RGLS | SELL | 2015-03-03 | $1K | — | Filing → |
| RGLS | SELL | 2015-02-03 | $112K | — | Filing → |
| RGLS | SELL | 2015-01-30 | $2.6M | — | Filing → |